Supplementary Figure 8 from SPP1+ Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8+ T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma

Key Points

• SPP1+ TAMs correlate with poor prognosis in patients with ccRCC, highlighting their role in promoting disease severity.
• Inhibition of CD8+ T-cell function by SPP1+ TAMs suggests a mechanism behind immunotherapy resistance in renal cell carcinoma.
• The study implies that targeting SPP1+ TAMs could improve treatment outcomes for ccRCC patients undergoing immunotherapy.
• Further investigation is needed to validate the prognostic value of SPP1+ TAMs in broader patient cohorts.

Abstract